Response by Aubdool et al to Letters Regarding Article, “A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Drs Jin-shan and Xue-bin for their comments concerning our article.1 We agree that the results were highly positive for protecting against cardiovascular dysfunction in the 2 murine models.1 Here are our answers to their questions:
We do not yet know the mechanisms involved in the protective effects of α–calcitonin gene-related peptide (CGRP) from an in vivo perspective. There is evidence from in vitro studies that CGRP has blood pressure–independent effects, as discussed in the article. However, this is the first time we have been able to use a CGRP agonist that is long-lasting in vivo.
We are asked about the mechanisms of α-CGRP involved in the ejection fraction–improving effects. This is partly answered in (1). We used …